In Gln-addicted HCC cells, a combinational treatment with CB-839 (glutaminase inhibitor) and V-9302 (an inhibitor targeting the ASCT2 transporter) produced better tumour inhibition than monotherapy with CB-839 alone. This evidence concerns the gene GLS and hepatocellular carcinoma.